The Centers for Medicare and Medicaid Services (CMS) has announced that it “fully expects” to reverse
Medicare Part B rate cuts for separately payable drugs acquired through the 340B Drug Pricing Program,
resulting in an estimated additional $1.96 billion for 340B hospitals. Learn more through this blog post released by Foley & Lardner.
The Center for Medicare and Medicaid Innovation (CMMI) is launching a long awaited new oncology model, the Enhancing Oncology Model (EOM). Learn more about the successor to the Oncology Care Model (OCM), which ended June 30, 2022, here.
Many California health care providers, including hospitals and physician groups, will soon be required to sign on to California’s first-ever statewide data sharing agreement governing the exchange of health and social services information. Learn more here.
Learn more about the new Special Fraud Alert published by the Office of Inspector General, U.S. Department of Health and Human Services on arrangements with telemedicine companies, setting forth seven characteristics OIG believes could suggest a given arrangement poses a heighted risk of fraud and abuse.
Learn about enforcement action taken by the US Centers for Medicare and Medicaid Services (CMS) in 2022 against hospitals, to enforce CMS's Hospital Price Transparency Rule that took effect on January 1, 2021.